December 19, 2025
Quadruple witching involves the simultaneous expiration of stock index futures, stock index options, stock options, and single stock futures, occurring 4-X a year.
More than $7.1 trillion in notional options exposure is set to expire, including roughly $5 trillion tied to the S&P 500 index and $880 billion linked to single stocks <Goldman>
As I have written; “It's been a good clue to be reducing “some” exposures, exiting some also-rans or questionable data delays”
Never leave retail investor uninformed … I say what others won’t, so you can do what others can’t!
December 18, 2025
Thursday, CAPR yells as the roller-coaster crests-up, now waiting for the downslide groan! Opened -$0.04, flipped +$0.66, mid-day to -$0.02 closing at +$0.04.
Doubts still abound re: regulatory fragility and marginal HOPE-3 results and valuation concerns remain a key hang-up!
CAPR remains a structurally challenged, chronically unprofitable company whose valuation is disconnected from fundamentals.
Despite years of promoting Deramiocel (CAP-1002) as a potential treatment for Duchenne muscular dystrophy (DMD); CAPR has yet to generate any meaningful/partnering revenue only losses, relying on repeated capital raises and marketing narratives to sustain operations.
December 19, 2025
Great tailwinds until headwinds threaten; I would be taking profit from these” covering” highs
RMi collects, curates, interprets and disseminates cell and gene therapy sector (C>) fact-based news, trusted and verified intel and share pricing data to bridge the gap to an investment decision
It’s not always time to buy or sell; but it is time to KNOW and why!
Never leave a retail investor uninformed!
TGIF
December 18, 2025
Thursday, CAPR yells as the roller-coaster crests-up, now waiting for the downslide groan! Opened -$0.04, flipped +$0.66, mid-day to -$0.02 closing at +$0.04. Doubts still abound re: regulatory fragility and marginal HOPE-3 results and valuation concerns remain a key hang-up! CAPR remains a structurally challenged, chronically unprofitable company whose valuation is disconnected from fundamentals. Despite years of promoting Deramiocel (CAP-1002) as a potential treatment for Duchenne muscular dystrophy (DMD); CAPR has yet to generate any meaningful/partnering revenue only losses, relying on repeated capital raises and marketing narratives to sustain operations.
December 12, 2025
Who is wasting lipstick on this pig? WHO and WHAT is CONNING “American” investors re Harvard Apparatus RT (OTVQB: HRGN), a Beijing, China percentage “owned” and run company … Patterns of share pricing manipulation? OTCQB: HRGN traded 12/11... +$0.12 with 4,615 shares traded after Thursday’s $0.00, Wednesday’s -$0.06 with 600 shares traded, Tuesday’s $0.00 with 600 shares traded and Monday’s (12/8) +$0.18 with 6,900 shares traded) – manipulating the downside, PONZI scheme? Cash starved, NO clinical data after 5-year ago IND. Accumulated deficit to date= $103.2 M in 12 years U.S. investors BEWARE, forewarned is forearmed?
December 5, 2025
CAPR is trading +1.00 at $26.32 The offering to close on or about 12/8/25. CAPR believes these pivotal study results, in addition to the evidence from the HOPE-2 and HOPE-2 OLE studies, position … clinical issues in the FDA’s Complete Response Letter received earlier this year, consistent with prior FDA guidance that HOPE-3 results should be sufficient to support regulatory approval.” However, there are significant execution and regulatory risks around Deramiocel, including shifting FDA guidance and development costs.
1 hour 59 min ago
RMi Closing Bell: Witching expiration “covering” drives volatility
11 hours 40 min ago
RMi Pre-opening: Quadruple Witching
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
